

References

I-89

1. Pereira JR, Cheng R, Orlando M, et.al. Elderly Subset Analysis of Randomized Phase III Study Comparing Prmetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. *Drugs for R&D*. 2013;13:289-296.
2. Lassrado S, Moras K, Jawahar G, et.al. Role of Concomitant Chemoradiation in Locally Advanced Head and Neck Cancers. *Asian Pacific Journal of Cancer Prevention*. 2014;15(10):4147-4152.
3. Drugs @ FDA. Carboplatin. U.S. Food and Drug Administration.
4. Carboplatin. DrugPoints Summary. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO. Accessed 01/10/2016.
5. NCCN Drugs & Biologics Compendium™. Paraplatin ® (Carboplatin) Copyright 2016. National Comprehensive Cancer Network (NCCN).
6. Sadhukha T, Prabha S. Encapsulation in Nanoparticles Improves Anti-cancer Efficacy of Carboplatin. *AAPS PharmSciTech*. 2014;15(4):1029-1038.
7. ECRI Institute. Ovarian Cancer. Technology Forecast. Updated 11 Sept. 2014. Web. 9 Jan. 2016.